Food and Drug Administration

Clinical Chemistry and Clinical Toxicology Devices Panel

  December 6, 2006

Slides

FDA

2006-4263s1_01 – Chemistry Branch Update – Carol C. Benson – FDA (pdf)

2006-4263s1_02 – Toxicology Diagnostic Device Update – Courtney C. Harper, Ph.D. – FDA (pdf)

2006-4263s1_03 – Lipoprotein Subfractions – Douglas Wood – FDA (pdf)

20036-4263s1_04 – A Perspective on HDL-LDL Subclass, Subspecies and Subfraction Analyses and Challenges for Standardization – Parvin P. Waymack, PhD – Centers for Disease Control & Prevention, Atlanta , GA (guest) (pdf)

Open Public Hearing

2006-4263oph1_01 – Lipid Panel to Lipoprotein Subclasses: Time for a Paradigm Shift – G. Russell Warnick – Berkeley HeartLab, Inc. (guest) (pdf)

2006-4263oph1_02 – A Review of the Guidelines and Future Targets of Therapies – Kenneth French – Atherotech, Inc. (guest) (pdf)

2006-4263oph1_03 – Differences in HDL Subfraction Distribution in Normolipidemic Versus Dyslipidemic Individuals – Nehemias Muniz, Jennifer Morais, Ph.D. – Quantimetrix Corp. Redondo Beach, CA (guest) (pdf)

2006-4263oph1_04 – LDL Subclasses and Carotid Atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) – Samia Mora, MD, MHS – Divisions of Preventive and Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School (guest) (pdf)

2006-4263oph1_05 - Clinical Utilization of Lipoprotein Subclasses in the Management of Cardiovascular Disease (CVD) Risk – William Cromwell, MD (guest) (pdf)

2006-4263oph1_06 – Use of Emerging Risk Factors: Why and On Whom – Herbert k. Naito, Ph.D., MBA – NorthStar Consulting Service, Cleveland, OH (guest) (pdf)

---

Up | AC Home Page